RBC Capital lowered the firm’s price target on Danaher (DHR) to $241 from $250 and keeps an Outperform rating on the shares as part of a broader research note on the Life Sciences Tools and Diagnostics sector. The firm is updating its model with “more realistic” multiples, the analyst tells investors in a research note. September isn’t a great month to own healthcare, and with a rebound still 2-3 quarters away, this isn’t the time to broadly own the sector, RBC added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Third Point boosts position in Nvidia, takes new stakes in Mr Cooper, Meta
- UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk
- 5 Overlooked ‘Strong Buy’ Stocks Analysts Believe Could Surprise Everyone
- Danaher Announces General Counsel’s Upcoming Departure
- Danaher names Jonathan Leiken as General Counsel